← All stories
Markets
Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247
TORONTO, Sept. 09, 2026 (GLOBE NEWSWIRE) — Satellos Bioscience (Nasdaq: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today announced the assignment of…
Covered by 1 outlet
All coverage · 1 article